TY - JOUR
AU - Schröder, S
AB - advanced 164. Phase II aclarubicin in cancer study: thyroid H. SAMONIGG, D.K. HOSSFELD, J. SPEHN, H. FILL, G. LEB, und Graz; Hamburg, Department Innsbruck Onkologie; available about the of Most cancer deal with doxorubicin mono- chemotherapy reports thyroid where remission rates of to 30% are found. Aclarubicin is an derivative therapy up anthracycline which exhibited low in both and clinical studies Aclarubicin to cardiotoxicity preclinical [1]. appears be as effective as doxorubicin in the of such as leukemia. treatment acute There¬ malignancies myeloid fore we the of aclarubicin as in a II of meta- investigated efficacy single therapeutic agent phase study static cancer. thyroid and methods: 24 with metastatic cancer underwent treatment Patients patients thyroid cytostatic in three Medical Centers. None of the had received treat¬ University patients previously cytostatic Medical of and ment. In the Centers Graz Innsbruck the received 25 University patients mg/m2 aclarubicin for four In the Medical Center of 30 was intravenously days. University Hamburg mg/m2 for four This was 3 weeks in each given intravenously days. 4-day therapy repeated every patient. Results: of achieved remission 5 23 4 into account the (22 CR, patients percent) (1 PR). Taking 3 with minor a tumor decrease 
TI - Prognostic factors in medullary thyroid carcinoma: histology, immunocytochemistry, DNA-content
JO - European Journal of Endocrinology
DO - 10.1530/acta.0.117s144-a
DA - 1988-04-01
UR - https://www.deepdyve.com/lp/oxford-university-press/prognostic-factors-in-medullary-thyroid-carcinoma-histology-MR05YPuhdV
SP - S144
EP - S145
VL - 117
IS - 4_Supplement
DP - DeepDyve
ER -